FDMT

4D Molecular Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · 4dmoleculartherapeutics.com

$9.44

Mkt Cap $493.5M

52w Low $3.00 69.0% of range 52w High $12.34

50d MA $9.35 200d MA $8.65

P/E (TTM) -3.8x

EV/EBITDA -2.6x

P/B 1.0x

Debt/Equity 0.0x

ROE -27.7%

P/FCF -4.0x

RSI (14) —

ATR (14) —

Beta 2.93

50d MA $9.35

200d MA $8.65

Avg Volume 762.8K

About

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial fo…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 18, 2026	AMC	-0.53	0.43	+181.1%	8.56	+16.1%	+4.9%	+0.6%	+7.8%	+7.2%	+15.4%	—
Nov 10, 2025	AMC	-1.02	-1.01	+1.0%	10.17	+1.5%	+6.2%	+7.9%	+1.1%	+6.1%	+7.7%	—
Aug 11, 2025	AMC	-0.88	-0.98	-11.4%	5.53	+0.0%	+11.2%	+20.6%	+28.4%	+31.3%	+31.5%	—
May 8, 2025	AMC	-0.84	-0.86	-2.4%	3.24	+0.3%	-4.9%	+2.5%	+0.9%	-3.4%	-1.2%	—
Feb 28, 2025	AMC	-0.80	-0.90	-12.5%	4.53	+0.9%	-8.6%	-12.4%	-8.2%	-8.6%	-10.2%	—
Nov 13, 2024	AMC	-0.67	-0.79	-17.9%	7.71	+2.1%	+4.0%	+14.5%	+7.9%	+12.5%	+9.1%	—
Aug 8, 2024	AMC	-0.72	-0.63	+12.5%	14.73	+6.4%	+0.5%	+1.8%	+1.4%	-2.0%	-0.3%	—
May 9, 2024	AMC	-0.73	-0.66	+9.6%	25.64	-1.8%	+0.2%	-0.3%	+0.4%	-0.2%	+0.0%	—
Feb 29, 2024	AMC	-0.68	-0.77	-13.2%	28.02	+2.7%	+4.8%	+2.6%	-3.5%	+0.9%	+5.3%	—
Nov 9, 2023	AMC	-0.67	-0.24	+64.2%	10.50	+5.7%	+5.2%	+0.3%	+5.6%	+5.3%	+5.0%	—
Aug 9, 2023	AMC	-0.77	-0.77	+0.0%	17.04	-2.2%	-2.3%	-1.8%	-1.8%	-2.2%	-6.5%	—
May 10, 2023	AMC	-0.88	-0.88	+0.0%	17.65	+0.8%	-4.2%	+1.5%	+1.0%	+1.4%	+3.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.98	$8.63	-3.9%	-4.1%	+2.8%	+2.2%	+10.0%	+13.4%
Mar 19	Chardan Capital	Maintains	Buy → Buy	—	$8.56	$9.94	+16.1%	+4.9%	+0.6%	+7.8%	+7.2%	+15.4%
Mar 19	RBC Capital	Maintains	Outperform → Outperform	—	$8.56	$9.94	+16.1%	+4.9%	+0.6%	+7.8%	+7.2%	+15.4%
Dec 18	Chardan Capital	Maintains	Buy → Buy	—	$9.21	$9.51	+3.3%	-5.6%	-5.8%	-5.4%	-14.2%	-12.1%
Nov 11	Barclays	Maintains	Overweight → Overweight	—	$10.17	$10.32	+1.5%	+6.2%	+7.9%	+1.1%	+6.1%	+7.7%
Nov 11	Chardan Capital	Maintains	Buy → Buy	—	$10.17	$10.32	+1.5%	+6.2%	+7.9%	+1.1%	+6.1%	+7.7%
Nov 11	RBC Capital	Maintains	Outperform → Outperform	—	$10.17	$10.32	+1.5%	+6.2%	+7.9%	+1.1%	+6.1%	+7.7%
Oct 21	RBC Capital	Maintains	Outperform → Outperform	—	$11.27	$11.14	-1.2%	-0.3%	-6.7%	-11.3%	+0.6%	+8.9%
Aug 12	Roth Capital	Maintains	Buy → Buy	—	$5.53	$5.53	+0.0%	+11.2%	+20.6%	+28.4%	+31.3%	+31.5%
Aug 12	Chardan Capital	Maintains	Buy → Buy	—	$5.53	$5.53	+0.0%	+11.2%	+20.6%	+28.4%	+31.3%	+31.5%
Aug 1	Chardan Capital	Maintains	Buy → Buy	—	$4.50	$5.28	+17.3%	+42.7%	+16.4%	+34.4%	+27.3%	+28.4%
Jul 3	Chardan Capital	Maintains	Buy → Buy	—	$4.31	$4.31	+0.0%	-1.6%	-8.4%	-2.1%	+2.6%	+0.9%
May 9	Barclays	Maintains	Overweight → Overweight	—	$3.24	$3.25	+0.3%	-4.9%	+2.5%	+0.9%	-3.4%	-1.2%
May 9	Goldman Sachs	Maintains	Buy → Buy	—	$3.24	$3.25	+0.3%	-4.9%	+2.5%	+0.9%	-3.4%	-1.2%
May 9	Chardan Capital	Maintains	Buy → Buy	—	$3.24	$3.25	+0.3%	-4.9%	+2.5%	+0.9%	-3.4%	-1.2%
Mar 10	BofA Securities	Maintains	Buy → Buy	—	$4.07	$4.10	+0.7%	-4.2%	+1.0%	+4.2%	+5.2%	+1.0%
Mar 4	Chardan Capital	Maintains	Buy → Buy	—	$4.14	$4.11	-0.7%	-4.1%	+0.5%	+0.0%	-1.7%	-5.8%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.53	$4.57	+0.9%	-8.6%	-12.4%	-8.2%	-8.6%	-10.2%
Mar 3	RBC Capital	Maintains	Outperform → Outperform	—	$4.53	$4.57	+0.9%	-8.6%	-12.4%	-8.2%	-8.6%	-10.2%
Feb 11	Chardan Capital	Maintains	Buy → Buy	—	$5.32	$5.19	-2.4%	-13.9%	-14.5%	-11.3%	-8.3%	-8.8%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.97	$6.09	+2.0%	-10.9%	-23.3%	-23.8%	-20.9%	-18.3%
Jan 13	Morgan Stanley	Maintains	Underweight → Underweight	—	$5.52	$5.30	-4.0%	-13.8%	-11.6%	-8.7%	-15.2%	-17.0%
Jan 13	Leerink Partners	Maintains	Outperform → Outperform	—	$5.52	$5.30	-4.0%	-13.8%	-11.6%	-8.7%	-15.2%	-17.0%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.52	$5.30	-4.0%	-13.8%	-11.6%	-8.7%	-15.2%	-17.0%
Dec 18	BofA Securities	Maintains	Buy → Buy	—	$6.32	$6.34	+0.3%	-5.5%	-8.5%	-0.2%	-7.0%	-8.1%
Nov 14	Chardan Capital	Maintains	Buy → Buy	—	$7.71	$7.87	+2.1%	+4.0%	+14.5%	+7.9%	+12.5%	+9.1%
Nov 14	RBC Capital	Maintains	Outperform → Outperform	—	$7.71	$7.87	+2.1%	+4.0%	+14.5%	+7.9%	+12.5%	+9.1%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.71	$7.87	+2.1%	+4.0%	+14.5%	+7.9%	+12.5%	+9.1%
Sep 23	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$11.90	$11.46	-3.7%	-2.4%	-3.4%	-5.2%	-7.9%	-9.0%
Sep 19	Chardan Capital	Maintains	Buy → Buy	—	$16.82	$17.39	+3.4%	-19.7%	-29.3%	-31.0%	-31.7%	-32.9%
Sep 19	Leerink Partners	Maintains	Outperform → Outperform	—	$16.82	$17.39	+3.4%	-19.7%	-29.3%	-31.0%	-31.7%	-32.9%
Sep 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.82	$17.39	+3.4%	-19.7%	-29.3%	-31.0%	-31.7%	-32.9%
Aug 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.73	$15.68	+6.4%	+0.5%	+1.8%	+1.4%	-2.0%	-0.3%
Jul 22	RBC Capital	Maintains	Outperform → Outperform	—	$14.40	$14.60	+1.4%	+18.6%	+24.6%	+24.6%	+28.6%	+27.4%
Jul 18	BMO Capital	Maintains	Outperform → Outperform	—	$18.20	$18.20	+0.0%	-16.8%	-20.9%	-6.2%	-1.4%	-1.4%
Jul 17	Chardan Capital	Maintains	Buy → Buy	—	$26.75	$28.89	+8.0%	-32.0%	-43.4%	-46.2%	-36.1%	-32.9%
Jun 26	RBC Capital	Maintains	Outperform → Outperform	—	$22.00	$21.93	-0.3%	-4.5%	-4.9%	-4.6%	-3.0%	-6.5%
Jun 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.57	$22.25	-1.4%	+0.7%	+0.0%	+3.2%	+6.6%	+8.2%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.70	$25.94	+0.9%	-0.5%	+0.2%	-0.5%	-0.2%	-1.4%
Apr 15	RBC Capital	Maintains	Outperform → Outperform	—	$26.35	$27.89	+5.8%	-0.4%	+1.5%	-4.0%	-6.0%	-4.2%
Apr 1	BMO Capital	Maintains	Outperform → Outperform	—	$31.86	$31.78	-0.3%	-5.8%	-12.2%	-12.4%	-13.2%	-10.2%
Apr 1	Jefferies	Maintains	Buy → Buy	—	$31.86	$31.78	-0.3%	-5.8%	-12.2%	-12.4%	-13.2%	-10.2%
Mar 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$28.02	$28.77	+2.7%	+4.8%	+2.6%	-3.5%	+0.9%	+5.3%
Feb 5	RBC Capital	Maintains	Outperform → Outperform	—	$17.49	$30.05	+71.8%	+84.6%	+89.9%	+61.5%	+53.8%	+63.7%
Feb 5	BMO Capital	Maintains	Outperform → Outperform	—	$17.49	$30.05	+71.8%	+84.6%	+89.9%	+61.5%	+53.8%	+63.7%
Jan 29	RBC Capital	Maintains	Outperform → Outperform	—	$17.50	$17.93	+2.5%	+3.0%	+2.0%	-1.4%	+6.7%	-0.1%
Aug 11	Chardan Capital	Maintains	Buy → Buy	—	$16.65	$16.64	-0.1%	+0.5%	+0.5%	+0.1%	-4.3%	-5.1%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.04	$16.66	-2.2%	-2.3%	-1.8%	-1.8%	-2.2%	-6.5%
Jul 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.34	$18.38	+0.2%	-0.2%	+0.8%	-0.5%	-1.7%	-1.1%
Jul 11	Chardan Capital	Maintains	Buy → Buy	—	$18.76	$19.14	+2.0%	+5.3%	+5.2%	+2.5%	+0.9%	-1.0%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

I cannot provide a meaningful analysis because the filing summary lacks critical details about which executive changed roles, their compensation, responsibilities, or whether the change signals strategic shifts or instability.

Mar 30

8-K

Unknown — 8-K Filing

4D Pharma's clinical progress on 4D-150 for wet AMD with pivotal data expected H1 2027 validates its pipeline potential, but investors should monitor cash runway closely given expanded leadership costs and late-stage development expenses.

Mar 18

Data updated apr 25, 2026 8:44am · Source: massive.com